343781-36-2

Basic information

• Product Name: 2,4-Dichloro-3-iodopyridine
• Synonyms: Pyridine, 2,4-dichloro-3-iodo-;2,4-dichloro-3-iodo-pyridine
• CAS NO: 343781-36-2
• Molecular Formula: C₅H₂Cl₂IN
• Molecular Weight: 273.89
• Product Categories: Heterocycle-Pyridine series
• Mol File: 343781-36-2.mol
• Article Data: 13

Chemical Properties

• Melting Point: 90-94℃
• Boiling Point: 290.343 °C at 760 mmHg
• Flash Point: 129.395 °C
• Appearance: /
• Density: 2.129g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.652
• Storage Temp.: 2-8°C(protect from light)
• PKA: -1.17±0.10(Predicted)
• CAS DataBase Reference: 2,4-Dichloro-3-iodopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-3-iodopyridine(343781-36-2)
• EPA Substance Registry System: 2,4-Dichloro-3-iodopyridine(343781-36-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• RIDADR: UN 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 343781-36-2(Hazardous Substances Data)

Usage

General Description

2,4-Dichloro-3-iodopyridine is a synthetic, organic compound that belongs to the family of halopyridines. 2,4-Dichloro-3-iodopyridine is a derivative of pyridine, featuring two chlorine atoms and one iodine atom on a six-atom pyridine ring. The existence of these halogen functionalities makes it an important compound in the field of medicinal chemistry and drug discovery. It also serves as an intermediate for the synthesis of other complex organic compounds. 2,4-Dichloro-3-iodopyridine is typically sold in light-tight containers and should be stored in a well-ventilated area due to its sensitivity to light. The chemical formula of 2,4-Dichloro-3-iodopyridine is C5H2Cl2IN.

InChI:InChI=1/C5H2Cl2IN/c6-3-1-2-9-5(7)4(3)8/h1-2H

Upstream product

• 1100932-71-5 2,4-dihydroxy-3-iodopyridine 
• 626-03-9 3-deazauracil 
• 26452-80-2 2,4-dichloropyridine 
• 78607-36-0 2-chloro-3-iodopyridine 
• 153034-86-7 2-chloro-4-iodopyridine 
• 109-09-1 2-chloropyridine 

Downstream Products

• 1163693-01-3 2-chloro-3-iodo-4-methoxypyridine 
• 1163693-02-4 2-chloro-4-methoxy-3-(trifluoromethyl)pyridine 
• 1374668-00-4 3-(cyclopropylmethyl)-7-{[(2*R)-2-(2,4-difluorophenyl)morpholin-4-yl]methyl}-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine 
• 1374667-99-8 2-[[3-(cyclopropylmethyl)-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridin-7-yl]methyl]-5-(2,4-difluorophenyl)-2,5-diazabicyclo[4.1.0]heptane (cis) 
• 1374667-69-2 3-(cyclopropylmethyl)-7-[[(2R)-2-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1374667-68-1 3-(cyclopropylmethyl)-7-[(3-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1374668-02-6 3-(cyclopropylmethyl)-7-{[3-(2,4-difluorophenyl)piperazin-1-yl]methyl}-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine 
• 1374667-73-8 3-(cyclopropylmethyl)-7-[(3-methyl-3-phenyl-l-piperazinyl)methyl]-8-(trifluoromethyl)-l,2,4-triazolo[4,3-a]pyridine 

Relevant articles and documents

INHIBITOR OF BTK AND MUTANTS THEREOF

The disclosure includes compounds of Formula (I) (1) wherein Q0, Q1, Q2, Q3, Q4, Z, W, i, j, m, n, Warhead, R0, R1, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

RADIOLABELLED mGLuR2 PET LIGANDS

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.